{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:25:16Z","timestamp":1773447916616,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.bmcl.2022.128667","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T13:33:41Z","timestamp":1646746421000},"page":"128667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva"],"prefix":"10.1016","volume":"64","author":[{"given":"Thomas","family":"Ullrich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Arista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Weiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Teixeira-Fouchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Broennimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Stiefl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Head","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Guth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bmcl.2022.128667_b0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ng1783","article-title":"A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva","volume":"38","author":"Shore","year":"2006","journal-title":"Nat Genet."},{"key":"10.1016\/j.bmcl.2022.128667_b0010","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4358","article-title":"ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A","author":"Hatsell","year":"20157303303137","journal-title":"Sci Transl Med."},{"issue":"1","key":"10.1016\/j.bmcl.2022.128667_b0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nchembio.2007.54","article-title":"Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism","volume":"4","author":"Yu","year":"2008","journal-title":"Nat Chem Biol."},{"issue":"15","key":"10.1016\/j.bmcl.2022.128667_b0020","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1016\/j.bmcl.2008.06.052","article-title":"Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors","volume":"18","author":"Cuny","year":"2008","journal-title":"Bioorg Med Chem Lett."},{"issue":"6","key":"10.1016\/j.bmcl.2022.128667_b0025","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1021\/cb300655w","article-title":"Development of an ALK2-biased BMP type I receptor kinase inhibitor","volume":"8","author":"Mohedas","year":"2013","journal-title":"ACS Chem Biol."},{"issue":"11","key":"10.1016\/j.bmcl.2022.128667_b0030","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1016\/j.bmcl.2013.03.113","volume":"23","author":"Engers","year":"2013","journal-title":"Bioorg Med Chem Lett."},{"issue":"32","key":"10.1016\/j.bmcl.2022.128667_b0035","doi-asserted-by":"crossref","first-page":"20729","DOI":"10.1021\/acsomega.1c02983","article-title":"Recent Advances in ALK2 Inhibitors","volume":"6","author":"Rooney","year":"2021","journal-title":"ACS Omega"},{"issue":"16","key":"10.1016\/j.bmcl.2022.128667_b0040","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1021\/acs.jmedchem.8b00782","article-title":"Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept","volume":"61","author":"Hudson","year":"2018","journal-title":"J Med Chem."},{"issue":"4","key":"10.1016\/j.bmcl.2022.128667_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062721","article-title":"A new class of small molecule inhibitor of BMP signaling","volume":"8","author":"Sanvitale","year":"2013","journal-title":"PLoS ONE"},{"issue":"19","key":"10.1016\/j.bmcl.2022.128667_b0050","doi-asserted-by":"crossref","first-page":"7900","DOI":"10.1021\/jm501177w","article-title":"Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants","volume":"57","author":"Mohedas","year":"2014","journal-title":"J Med Chem."},{"issue":"7","key":"10.1016\/j.bmcl.2022.128667_b0055","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/00498258609043552","article-title":"The trans-cis isomerization of trans-4'-(2-hydroxy-3,5-dibromo-benzylamino)cyclohexanol in vivo and in vitro in different species","volume":"16","author":"Bauer","year":"1986","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bmcl.2022.128667_b0060","unstructured":"PDB 10.2210\/pdb6EIX\/pdb."},{"key":"10.1016\/j.bmcl.2022.128667_b0065","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des Devel Ther."},{"issue":"3","key":"10.1016\/j.bmcl.2022.128667_b0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat Biotechnol."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22001433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22001433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:44:29Z","timestamp":1760773469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22001433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":14,"alternative-id":["S0960894X22001433"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128667","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128667"}}